We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 68.00
Bid: 68.00
Ask: 70.00
Change: 0.90 (1.32%)
Spread: 2.00 (2.941%)
Open: 68.00
High: 68.60
Low: 68.00
Prev. Close: 68.10
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

19 Jul 2019 07:03

RNS Number : 0930G
Novacyt S.A.
19 July 2019
 

 

 

Novacyt S.A.

 

("Novacyt" or the "Company")

 

Results of AGM and EGM Update

 

Paris, France and Camberley, UK - 19 July 2019 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) an international specialist in clinical diagnostics, announces that all resolutions proposed at the Annual General Meeting, held today, were duly passed.

 

The Company also met today to hold its Extraordinary General Meeting (EGM). The meeting was not deemed quorate due to the required minimum number of voting rights under French company law not being present or represented at the meeting. Consequently, the Company will reconvene an EGM at a later date.

 

- End -

 

For further information, please refer to www.novacyt.com or contact:

 

 

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1223 395472

 

SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)

Matthew Johnson / Jamie Spotswood (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

WG Partners (Joint Broker)

Nigel Birks / Chris Lee / Claes Spång

+44 (0) 203 705 9330

 

FTI Consulting (International)

Brett Pollard / Victoria Foster Mitchell/ Mary Whittow

+44 (0)20 3727 1000

brett.pollard@fticonsulting.com/victoria.fostermitchell@fticonsulting.com/ Mary.whittow@fticonsulting.com 

 

FTI Consulting (France)

Arnaud de Cheffontaines / Astrid Villette

+33 (0)147 03 69 47 / +33 (0)147 03 69 51

arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide. The Group directly serves oncology, microbiology, haematology and serology markets as do its global partners, which include major corporates.

 

For more information please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGQKLBFKDFBBBF
Date   Source Headline
26th May 20237:00 amRNSPublication of Annual Report and AGM voting
10th May 20237:00 amRNSNotice of AGM
2nd May 202312:30 pmRNSTotal Voting Rights
27th Apr 20237:00 amRNSFinal Results
17th Apr 20237:00 amRNSNotice of Results
3rd Apr 20231:00 pmRNSLiquidity Agreement and Total Voting Rights
1st Mar 20234:15 pmRNSLiquidity Agreement and Total Voting Rights
1st Feb 20231:30 pmRNSLiquidity Agreement and Total Voting Rights
30th Jan 20237:00 amRNSDHSC Claim update – Trial date listed
26th Jan 20237:00 amRNSFull Year 2022 Trading Update
6th Jan 202312:15 pmRNSHoldings in Company
3rd Jan 202312:30 pmRNSLiquidity Agreement and Total Voting Rights
7th Dec 20227:00 amRNSNon-Executive Director Change
6th Dec 20227:00 amRNSApproval of genesig COVID-19 3G PCR test in UK
1st Dec 20225:00 pmRNSLiquidity Agreement and Total Voting Rights
10th Nov 20227:00 amRNSDirectorate Change
1st Nov 20225:00 pmRNSLiquidity Agreement and Total Voting Rights
27th Oct 20226:45 pmRNSCORRECTION: UK CTDA approval of Winterplex 3G
26th Oct 20227:00 amRNSUK Approval of genesig® SARS-CoV-2 Winterplex® 3G
3rd Oct 20223:30 pmRNSLiquidity Agreement and Total Voting Rights
29th Sep 20227:00 amRNSHalf year 2022 results
15th Sep 20227:00 amRNSNotice of Results and Investor Presentation
1st Sep 202212:00 pmRNSLiquidity Agreement and Total Voting Rights
4th Aug 20227:00 amRNSLaunch of first fully lyophilised PROmate® assays
1st Aug 20222:30 pmRNSLiquidity Agreement and Total Voting Rights
28th Jul 20227:00 amRNSLaunch of research-use-only adenovirus F41 assay
20th Jul 20223:00 pmRNSResults of AGM
15th Jul 20227:00 amRNSDirector/PDMR Shareholding
15th Jul 20227:00 amRNSApproval of exsig™ COVID-19 Direct test in the UK
7th Jul 20223:00 pmRNSDirector/PDMR Shareholding
7th Jul 20227:00 amRNSTrading update and progress against strategy
5th Jul 202211:45 amRNSHoldings in Company
1st Jul 202212:30 pmRNSLiquidity Agreement and Total Voting Rights
28th Jun 20227:00 amRNSLaunch of monkeypox assay
21st Jun 20222:00 pmRNSNotice of rescheduled AGM
16th Jun 20227:00 amRNSDHSC dispute update
13th Jun 20227:00 amRNSAGM Voting
1st Jun 20221:00 pmRNSLiquidity Agreement and Total Voting Rights
1st Jun 20227:00 amRNSCTDA approval and CE mark
1st Jun 20227:00 amRNSPublication of Annual Report and AGM voting
13th May 20227:00 amRNSNotice of Annual General Meeting
3rd May 202212:21 pmRNSLiquidity Agreement Update and Total Voting Rights
28th Apr 20227:00 amRNSFull year results and update on growth strategy
26th Apr 20227:00 amRNSDHSC dispute update
20th Apr 20227:00 amRNSNotice of Results and Investor Presentation
12th Apr 20227:00 amRNSApproval of COVID-19 test under CTDA legislation
1st Apr 202211:45 amRNSLiquidity Agreement Update and Total Voting Rights
25th Mar 20225:25 pmRNSDirector/PDMR Shareholding
18th Mar 20226:00 pmRNSDirector/PCA Dealing
15th Mar 20222:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.